Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study - 24/04/13
Abstract |
Background |
The use of light-emitting diode light offers practical advantages in photodynamic therapy (PDT) with topical methyl-aminolevulinate (MAL) for management of actinic keratoses (AK).
Objective |
We sought to evaluate the efficacy of MAL PDT using red light-emitting diode light.
Methods |
We conducted a multicenter, double-blind, randomized study. A total of 49 patients with 363 AK lesions had 16.8% MAL cream applied under occlusion for 3 hours, and 47 patients with 360 AK lesions had vehicle cream similarly applied. The lesions were then illuminated (630 nm, light dose 37 J/cm2) with repeated treatment 1 week later. Complete lesion and patient (all lesions showing complete response) response rates were evaluated 3 months after last treatment.
Results |
MAL PDT was superior (P < .0001) to vehicle PDT with respect to lesion complete response (86.2% vs 52.2%, odds ratio 6.9 [95% confidence interval 4.7-10.3]) and patient complete response (59.2% vs 14.9%, odds ratio 13.2 [95% confidence interval 4.1-43.1]).
Limitations |
The study population may not be representative of all patients with AK.
Conclusion |
MAL PDT using red light-emitting diode light is an appropriate treatment alternative for multiple AK lesions.
Le texte complet de cet article est disponible en PDF.Abbreviations used : AK, CI, LED, MAL, PDT
Plan
Supported by PhotoCure ASA, Oslo, Norway. |
|
Disclosure: The authors certify that, to their knowledge, the work that is reported on in said manuscript has not received financial support from any pharmaceutical company or other commercial source except as described below. Neither the authors nor any first-degree relative have any special financial interest in the subject matter discussed in said manuscript. Dr Pariser has received grants for participation in clinical trials from PhotoCure ASA, Galderma, and DUSA. Dr Loss has received grants for participation in clinical trials from DOW, Genentech, Connetics, Allergan, Galderma, Hill, Centocor, Stiefel, and Novartis. Dr Abramovits has received grants for participation in clinical trials from Galderma. Dr Bruce has received grants for participation in clinical trials from Allergan, Medicis, Altana, Astellas, Galderma, 3M, Connetics, Obagi, Dow, DUSA, Hill, Isolagen, Novartis, Contura, and Anacor; has received honoraria for participation in advisory boards from Allergan and Syneron; has received honoraria as a consultant for Dermik and Medicis; and has received honoraria as a speaker for Dermik and Obagi. All authors received a grant for participation in this trial from PhotoCure ASA. |
|
Reprints not available from the authors. |
Vol 59 - N° 4
P. 569-576 - octobre 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?